A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center may help explain why certain liver ...

Researchers in gastroenterology and hepatology at HKUMed are pioneering gene-related therapy for chronic hepatitis B infection, potentially enabling ...

The fluorescent labeling compound—dubbed "Sialyl Lewis Yellow"—was developed by an international team led from the Pohang University of Science and Technology in South Korea. It works by binding to ...

New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for ...

Four years after pre-surgery treatment with a novel combination of immune checkpoint inhibitors, nivolumab and relatlimab, 87 ...

Scientists at The Wistar Institute have discovered that a class of FDA-approved cancer drugs known as PARP1 inhibitors can effectively combat Epstein-Barr virus (EBV)-driven lymphomas. The findings, ...

The signature of the financial agreement is in line with previous announcements on January 24, 2025, and April 24, 2025 stating that Median and the EIB were working to conclude an agreement for a new ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...